ADA-friendly PDF: Synergistic cytotoxicity of interferon-2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy

Synergistic cytotoxicity of interferon-2b and interleukin-2 in combination with PBMC against ovarian cancer: Development of an experimental model for cellular therapy

Current therapies for ovarian cancer (OC) patients have a modest impact on long-term survival justifying the need for novel treatment strategies. We developed in vitro and in vivo systems to test the effects of cytokines in combination with peripheral blood mononuclear cells (PBMC) on OC cells.